| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15229 R63061 |
Dreier (Lamotrigine) (Epilepsy) (Controls unexposed, sick), 2023 | Attention-deficit/hyperactivity disorder (ADHD) - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 0.83 [0.66;1.04] | 95/5,288 528/22,203 | 623 | 5,288 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8956 R39729 |
Wiggs (Lamotrigine), 2020 | Attention-deficit/hyperactivity disorder (after 2 years of age) | at least 1st trimester | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 1.00 [0.59;1.69] | -/- -/11,298 | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8951 R39716 |
Richards (Lamotrigine) (Indications NOS), 2019 | The Strengths and Difficulties Questionnaire - parent-completed (SDQP) Hyperactivity ≥7 (at 4 years old) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes | 2.15 [1.21;3.81] | 13/149 11,841/286,966 | 11,854 | 149 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8933 R39738 |
Bromley (Lamotrigine) (Controls unexposed, disease free), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
7.24 [0.14;371.71] C excluded (control group) |
0/30 0/214 | 0 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8936 R39741 |
Bromley (Lamotrigine) (Controls unexposed, sick), 2013 | Attention deficit hyperactivity disorder (at 6 years old) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.86 [0.02;45.15] C | 0/30 0/26 | 0 | 30 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8952 R39718 |
Rihtman (Lamotrigine), 2013 | Conners’ Parent - ADHD Index (mean age 4-5 years old) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) | 1.21 [0.57;2.56] | -/39 -/52 | - | 39 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8953 R39722 |
Veiby (Lamotrigine) (Controls unexposed, disease free) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
1.50 [0.40;4.80] excluded (control group) |
3/44 1,743/43,571 | 1,746 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8954 R39723 |
Veiby (Lamotrigine) (Controls unexposed, sick) b, 2013 | ADHD symptoms ≥ 2SD (at 36 months) (Specific checklist) (Parent-reported) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 2.74 [0.59;12.75] C | 3/44 4/154 | 7 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.21 [0.81;1.81] | 12,484 | 5,550 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Lamotrigine) (Epilepsy) (Controls unexposed, sick; 2: Lamotrigine; 3: Lamotrigine) (Indications NOS; 4: Lamotrigine) (Controls unexposed, sick; 5: Lamotrigine; 6: Lamotrigine) (Controls unexposed, sick) ;
Asymetry test p-value = 0.1965 (by Egger's regression)
slope=-0.2723 (0.2078); intercept=1.3679 (0.8837); t=1.5480; p=0.1965
excluded 8933, 8953